FI82253C - Foerfarande foer framstaellning av farmakologiskt vaerdefulla tigogencellubiocider. - Google Patents

Foerfarande foer framstaellning av farmakologiskt vaerdefulla tigogencellubiocider. Download PDF

Info

Publication number
FI82253C
FI82253C FI842935A FI842935A FI82253C FI 82253 C FI82253 C FI 82253C FI 842935 A FI842935 A FI 842935A FI 842935 A FI842935 A FI 842935A FI 82253 C FI82253 C FI 82253C
Authority
FI
Finland
Prior art keywords
tigogenin
cholesterol
anomer
mixture
cellubicide
Prior art date
Application number
FI842935A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI82253B (fi
FI842935A0 (fi
FI842935L (fi
Inventor
Malinow Rene M
Original Assignee
Oregon Medical Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Medical Res Found filed Critical Oregon Medical Res Found
Publication of FI842935A0 publication Critical patent/FI842935A0/fi
Publication of FI842935L publication Critical patent/FI842935L/fi
Publication of FI82253B publication Critical patent/FI82253B/fi
Application granted granted Critical
Publication of FI82253C publication Critical patent/FI82253C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0013—Details of inhalators; Constructional features thereof with inhalation check valves
    • A61M15/0015—Details of inhalators; Constructional features thereof with inhalation check valves located upstream of the dispenser, i.e. not traversed by the product
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0013—Details of inhalators; Constructional features thereof with inhalation check valves
    • A61M15/0016—Details of inhalators; Constructional features thereof with inhalation check valves located downstream of the dispenser, i.e. traversed by the product
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0086—Inhalation chambers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Anesthesiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Cephalosporin Compounds (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
FI842935A 1984-04-20 1984-07-23 Foerfarande foer framstaellning av farmakologiskt vaerdefulla tigogencellubiocider. FI82253C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/602,298 US4602005A (en) 1982-05-17 1984-04-20 Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US60229884 1984-04-20

Publications (4)

Publication Number Publication Date
FI842935A0 FI842935A0 (fi) 1984-07-23
FI842935L FI842935L (fi) 1985-10-21
FI82253B FI82253B (fi) 1990-10-31
FI82253C true FI82253C (fi) 1991-02-11

Family

ID=24410793

Family Applications (2)

Application Number Title Priority Date Filing Date
FI842935A FI82253C (fi) 1984-04-20 1984-07-23 Foerfarande foer framstaellning av farmakologiskt vaerdefulla tigogencellubiocider.
FI900531A FI87792C (fi) 1984-04-20 1990-02-02 Tigogenin-cellubiosid-okta-acetat

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI900531A FI87792C (fi) 1984-04-20 1990-02-02 Tigogenin-cellubiosid-okta-acetat

Country Status (16)

Country Link
US (1) US4602005A (https=)
EP (1) EP0159431B1 (https=)
JP (1) JPS60224697A (https=)
KR (1) KR940002114B1 (https=)
AT (1) ATE42959T1 (https=)
AU (1) AU580005B2 (https=)
CA (1) CA1246544A (https=)
DE (1) DE3478114D1 (https=)
DK (2) DK165839C (https=)
ES (1) ES534553A0 (https=)
FI (2) FI82253C (https=)
HU (1) HUT37802A (https=)
IE (1) IE58015B1 (https=)
NO (1) NO842990L (https=)
NZ (1) NZ208961A (https=)
ZA (1) ZA845690B (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US4865850A (en) * 1986-09-08 1989-09-12 See/Shell Biotechnology, Inc. Dietary fat reduction
US5010185A (en) * 1989-06-13 1991-04-23 Pfizer Inc. Processes for tigogenin beta-cellobioside
US5091192A (en) * 1990-01-16 1992-02-25 Natur-All Systems, Inc. Bile salts permanently bound to insoluble cellulose as a dietary supplement
CA2079544A1 (en) * 1991-10-04 1993-04-05 Adam Weislaw Mazur Cholesterol lowering compounds
ES2114948T3 (es) * 1991-10-04 1998-06-16 Procter & Gamble Compuestos disminuidores del colesterol y procedimiento para prepararlos.
JPH0826064B2 (ja) * 1991-11-25 1996-03-13 ファイザー インク． ステロイドペルアシルグリコシド類の製法
US5294703A (en) * 1992-05-01 1994-03-15 Eastman Kodak Company Process for preparing α-D-cellobiose octaacetate
WO1994000478A1 (en) * 1992-06-26 1994-01-06 Pfizer Inc. Steroidal beta-o-cellobioside heptaalkanoate process
AU4044293A (en) * 1992-06-26 1994-01-24 Pfizer Inc. Process for steroidal peracyl glycosides
EP0647234A1 (en) * 1992-06-26 1995-04-12 Pfizer Inc. Steroidal glycosides for treating hypercholesterolemia
US5530107A (en) * 1992-10-15 1996-06-25 Pfizer Inc. Method for making steroidal peracyl glycosides
CA2161239A1 (en) * 1993-04-28 1994-11-10 Douglas J.M. Allen Spirostanyl glycosidal crystalline monohydrate
US5502038A (en) * 1993-06-21 1996-03-26 Medical Research Foundation Of Oregon Cholesterol sequestrant glycosides that inhibit intestinal cholesterol absorption
AU7250694A (en) * 1993-06-25 1995-01-17 Biosphere Technologies Inc. Dietary supplement incorporating beta-sitosterol and pectin
ES2074006B1 (es) * 1993-07-05 1996-03-16 Pfizer Glicosidos esteroidales para tratar hipercolesterolemia.
EP0737203A1 (en) * 1993-12-28 1996-10-16 Pfizer Inc. Steroidal glycosides
US5607841A (en) * 1994-06-20 1997-03-04 Lipinski; Boguslaw Preparation and proteolytic degradation of a macromolecular protein complex from fibrinogen
JPH09511753A (ja) * 1994-09-20 1997-11-25 ファイザー・インコーポレーテッド コレステロール吸収阻害薬とコレステロール合成阻害薬の併用
US6150336A (en) * 1995-05-29 2000-11-21 Pfizer Inc. Steroidal glycosides
US5698527A (en) * 1995-08-08 1997-12-16 Merck & Co., Inc. Steroidal glycosides as antihyperlipidemic agents
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
BR9909110A (pt) * 1998-03-26 2000-12-12 Phytopharm Plc Usos de esmilagenina e anzurogenina d, compoisção farmacêutica tendo propriedades intensificadoras da função cognitiva, processo para intensificar a função cognitiva, e, composição para uso do mesmo
GB9923076D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923077D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) * 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
WO2002058685A2 (en) * 2001-01-26 2002-08-01 Schering Corporation Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
WO2002058733A2 (en) * 2001-01-26 2002-08-01 Schering Corporation Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
AR035533A1 (es) * 2001-01-26 2004-06-02 Schering Corp Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
PT1385548E (pt) * 2001-01-26 2007-08-24 Schering Corp Combinações de um inibidor ou de inibidores de absorção de esteróis com agente (s) para o tratamento de doenças vasculares
IL156445A0 (en) * 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
SK9502003A3 (en) * 2001-01-26 2003-12-02 Schering Corp Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
GB0107822D0 (en) * 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
ES2275007T3 (es) * 2001-05-25 2007-06-01 Schering Corporation Uso de derivados de azetidinona sustitudos en el tratamiento de la enfermedad de alzeimer.
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
MXPA04002573A (es) * 2001-09-21 2004-06-18 Schering Corp Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
HUP0401501A3 (en) * 2001-09-21 2012-02-28 Schering Corp Treating or preventing vascular inflammation using pharmaceutical compositions containing sterol absorption inhibitor(s)
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US20050130948A1 (en) * 2002-03-27 2005-06-16 Daryl Rees Therapeutic methods and uses of sapogenins and their derivatives
KR101130212B1 (ko) * 2002-03-27 2012-04-13 파이토팜 피엘씨 사포게닌 및 그 유도체의 치료 방법 및 사용법
WO2004043457A1 (en) * 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
JP2006519869A (ja) * 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
CA2517572C (en) * 2003-03-07 2011-12-13 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
EP1601668B1 (en) 2003-03-07 2008-08-27 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2007510659A (ja) * 2003-11-05 2007-04-26 シェーリング　コーポレイション 脂質調節剤および置換アゼチジノンの組み合わせならびに血管状態の処置
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
WO2005063790A1 (en) * 2003-12-31 2005-07-14 Council Of Scientific & Industrial Research Isolation of tigogenin pentaglycoside from chlorophytum nimonii
US7160866B2 (en) 2004-03-22 2007-01-09 Council Of Scientific And Industrial Research Isolation of tigogenin pentaglycoside from Chlorophytum nimonii

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2759171A1 (de) * 1977-12-31 1979-07-12 Roecar Holdings Nv Arzneimittel mit wirkung als prostaglandinsynthetaseninhibitor
DE2926463A1 (de) * 1978-07-05 1980-01-24 Roecar Holdings Nv Spiroketaline und ihre verwendung
US4260603A (en) * 1979-01-02 1981-04-07 Pegel Karl H Sterol glycoside with activity as prostaglandin synthetase inhibitor
US4242502A (en) * 1979-04-20 1980-12-30 United States Of America Enhancement of cholesterol combining properties of saponins
US4602003A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis

Also Published As

Publication number Publication date
FI82253B (fi) 1990-10-31
DK165839B (da) 1993-01-25
FI900531A0 (fi) 1990-02-02
IE841904L (en) 1985-10-20
US4602005A (en) 1986-07-22
ES8601233A1 (es) 1985-11-16
DK166213B (da) 1993-03-22
FI842935A0 (fi) 1984-07-23
ZA845690B (en) 1986-03-26
EP0159431A2 (en) 1985-10-30
JPS60224697A (ja) 1985-11-09
FI87792B (fi) 1992-11-13
DK165839C (da) 1993-06-21
ATE42959T1 (de) 1989-05-15
NO842990L (no) 1985-10-21
JPH0456840B2 (https=) 1992-09-09
DE3478114D1 (en) 1989-06-15
DK14892A (da) 1992-02-06
IE58015B1 (en) 1993-06-16
EP0159431A3 (en) 1986-01-08
KR940002114B1 (ko) 1994-03-17
HUT37802A (en) 1986-02-28
AU580005B2 (en) 1988-12-22
FI842935L (fi) 1985-10-21
CA1246544A (en) 1988-12-13
FI87792C (fi) 1993-02-25
DK361084D0 (da) 1984-07-23
EP0159431B1 (en) 1989-05-10
DK166213C (da) 1993-08-16
AU3097784A (en) 1985-10-24
NZ208961A (en) 1988-01-08
DK361084A (da) 1985-10-21
KR850007432A (ko) 1985-12-04
ES534553A0 (es) 1985-11-16
DK14892D0 (da) 1992-02-06

Similar Documents

Publication Publication Date Title
FI82253C (fi) Foerfarande foer framstaellning av farmakologiskt vaerdefulla tigogencellubiocider.
US5369096A (en) Glycolipid derivatives
US6017892A (en) Method for accelerating marrow cell proliferation
JP3074733B2 (ja) 脂肪乳剤
US20040014806A1 (en) Methods and compositions for lowering levels of blood lipids
EP0237051A2 (en) Prodrug compounds, process for the preparation thereof and sustained release preparation comprising the same
JPH07501341A (ja) 細胞接着阻害剤としての置換されたラクトースおよびラクトサミン誘導体
EP0488513B1 (en) Use of dioxabicyclo [3.3.0]octane derivatives for the manufacture of a medicament for inhibiting the metabolism of cholesterol.
EP1172107B1 (en) Drugs containing sulfopyranosylacylglycerol derivatives
JPS62258366A (ja) 置換ピリミジンアミド
CH683427A5 (fr) Composé d'isoquinoléine comme agents de blocage neuromusculaire.
KR100195421B1 (ko) 6-아미노옥타히드로인돌리진트리올유도체
JPH1067656A (ja) 細胞接着抑制剤
EP0180980A2 (en) Lipid membrane structures
MC2164A1 (fr) Steroides
JP2647882B2 (ja) 鮫組織から単離した有効成分
EP0082818A1 (fr) Procédé pour l'obtention de lipides d'origine humaine et du lacto-N-norhexaosyl ceramide
CA2364446C (en) Novel immunosuppressive agent
KR20060028630A (ko) 이노시톨 폴리포스페이트 유도체 및 그의 사용 방법
WAGO Antiatherosclerotic and anticoagulant activity of cerebroside sulfate
US6136800A (en) 17-Difluoromethylene-estratrienes
US6057308A (en) Remedy or preventive for hyperlipemia
KR20000016565A (ko) 폴리올 숙시네이트 및 이의 약제학적 제제
KR20010012764A (ko) 2,3-디히드로벤조푸란 유도체
EP0510197A1 (en) Fat emulsion

Legal Events

Date Code Title Description
MM Patent lapsed

Owner name: MEDICAL RESEARCH FOUNDATION OF OREGON